Concurrent temozolomide [TMZ] and irradiation for the management of high grade malignant glioma
Medical Journal of Cairo University [The]. 2003; 71 (Supp. 2): 147-156
en Inglés
| IMEMR
| ID: emr-63816
ABSTRACT
This pilot study was conducted on 18 newly diagnosed patients with malignant glioma [11 patients with glioblastoma multiforme [GBM] and 7 patients with anaplastic astrocytoma [AA]] to assess the safety, tolerability and efficacy of concurrent administration of temozolomide [TMZ] and radiation. The eligible patients received 40 Gy [1.8 Gy/fraction, 1 fraction/day, 5 days/week] to the computed tomography [CT] or magnetic resonance imaging [MRI] enhancing lesion and surrounding edema with a 3 cm margin, then 20 Gy to a smaller volume including the contrast enhancing lesion plus 1-2 cm margin. Starting from the first day of radiation, the patients received oral TMZ [150 mg/m2] daily for 5 days and repeated every 28 days for two cycles. The study demonstrated the safety and efficacy of concurrent TMZ with radiation in newly diagnosed high grade gliomas and supported a further continued investigation of low daily dose TMZ with concurrent radiation, preferably with some cycles of TMZ as an adjuvant to radiation, in a multicenter phase III randomized trial containing a large number of patients and comparing this regimen with radiotherapy alone in newly diagnosed high-grade astrocytomas
Buscar en Google
Índice:
IMEMR (Mediterraneo Oriental)
Asunto principal:
Astrocitoma
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Tasa de Supervivencia
/
Estudios de Seguimiento
/
Resultado del Tratamiento
/
Glioblastoma
/
Imidazoles
Tipo de estudio:
Ensayo Clínico Controlado
Límite:
Femenino
/
Humanos
/
Masculino
Idioma:
Inglés
Revista:
Med. J. Cairo Univ.
Año:
2003
Similares
MEDLINE
...
LILACS
LIS